Fluorescence Guided Surgery Therapeutics
1. Cytalux patent expiration
Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9333270 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(7 years from now) | |
| US9061057 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(7 years from now) | |
| US10881747 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(7 years from now) | |
| US9789208 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(7 years from now) | |
| US9254341 | ON TARGET LABS | Methods of manufacture of pteroyl-amino acid-fluorescent dyes |
Oct, 2033
(7 years from now) | |
| US9341629 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-905) | Dec 16, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2026 |
| Orphan Drug Exclusivity(ODE-390) | Nov 29, 2028 |
Drugs and Companies using PAFOLACIANINE SODIUM ingredient
NCE-1 date: 29 November, 2025
Market Authorisation Date: 29 November, 2021
Dosage: SOLUTION
More Information on Dosage
CYTALUX family patents
2. Lumisight patent expiration
Treatment: A method comprising administering pegulicianine to a human and obtaining an image of a tumor bed after tumor resection to distinguish in situ cancer cells from healthy cells
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9763577 | LUMICELL | Imaging agent for detection of diseased cells |
Sep, 2034
(8 years from now) | |
| US11592396 | LUMICELL | Methods and systems for spatially identifying abnormal cells |
Sep, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9532835 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(5 years from now) | |
| US9155471 | LUMICELL | Methods and systems for spatially identifying abnormal cells |
Oct, 2031
(5 years from now) | |
| US9032965 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(5 years from now) | |
| US10285759 | LUMICELL | Methods and system for image guided cell ablation with microscopic resolution |
Dec, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2029 |
Drugs and Companies using PEGULICIANINE ACETATE ingredient
NCE-1 date: 17 April, 2028
Market Authorisation Date: 17 April, 2024
Dosage: POWDER
More Information on Dosage
LUMISIGHT family patents